A 26-year-old woman from Mumbai attends the infertility clinic with a 2-year history of anovulation. She has a BMI of 32 kg/m², irregular menses (cycles 45–90 days), and mild hirsutism. Pelvic ultrasound confirms polycystic ovaries. Hormonal profile: FSH 5.2 mIU/mL, LH 14 mIU/mL, total testosterone 0.9 ng/mL, fasting glucose 108 mg/dL, fasting insulin 22 mIU/mL. She has been on metformin 1500 mg daily for 6 months with minimal improvement in cycle regularity. She denies desire for contraception. What is the most appropriate next step in management?

Explanation

## Clinical Context: Anovulatory PCOS Seeking Fertility This patient has: - Confirmed PCOS (polycystic ovaries + anovulation + hyperandrogenism) - Persistent insulin resistance despite 6 months of metformin (fasting insulin 22 mIU/mL) - Desire for fertility (not contraception) - Adequate response to metformin metabolically (fasting glucose 108 mg/dL is borderline; no progression to diabetes) **Key Point:** The goal here is **ovulation induction**, not just menstrual regulation. Clomiphene citrate is the first-line ovulation-induction agent in PCOS-related anovulation. ## Why Clomiphene Citrate is Correct ### Mechanism & Efficacy 1. **Selective estrogen receptor modulator (SERM):** Blocks negative feedback of estrogen at the hypothalamus and pituitary 2. **Increases FSH secretion** → stimulates follicular growth → ovulation 3. **Ovulation rate:** 70–80% in PCOS; pregnancy rate 30–40% over 6 cycles 4. **Ideal for insulin-resistant PCOS:** Works independently of insulin levels 5. **Safe:** Minimal side effects; low risk of ovarian hyperstimulation syndrome (OHSS) ### Dosing & Protocol - **Starting dose:** 50 mg daily for 5 days (days 3–7 or 5–9 of cycle) - **Escalation:** 100 mg, then 150 mg if anovulation persists - **Monitoring:** Transvaginal ultrasound on day 12–14 to confirm follicular growth and ovulation - **Duration:** Up to 6 ovulatory cycles before considering next-line therapy **High-Yield:** Clomiphene is first-line for anovulatory PCOS seeking pregnancy. It is cheaper, safer, and more effective than gonadotropins for initial therapy. ## Comparison: Ovulation-Induction Agents in PCOS | Agent | Mechanism | Ovulation Rate | Pregnancy Rate | OHSS Risk | Cost | First-Line? | |-------|-----------|---|---|---|---|---| | **Clomiphene citrate** | SERM → ↑ FSH | 70–80% | 30–40% | <1% | Low | **Yes** | | **Letrozole** | Aromatase inhibitor | 60–70% | 25–35% | <1% | Moderate | Alternative | | **Gonadotropins (FSH/hCG)** | Direct ovarian stimulation | 90% | 40–50% | 5–10% | High | Third-line | | **Metformin alone** | ↓ Insulin → ↑ FSH | 20–30% | 10–20% | Rare | Low | Adjunctive | **Clinical Pearl:** Metformin + clomiphene combination has superior ovulation and pregnancy rates (50–60%) compared to either agent alone in insulin-resistant PCOS. This patient should continue metformin and add clomiphene. ## Treatment Algorithm for Anovulatory PCOS Seeking Fertility ```mermaid flowchart TD A[Anovulatory PCOS, wants pregnancy]:::outcome --> B[Optimize BMI, continue metformin]:::action B --> C{Ovulating after 3–6 months metformin?}:::decision C -->|Yes| D[Timed intercourse, monitor]:::action C -->|No| E[Add clomiphene 50 mg days 5-9]:::action E --> F{Follicular growth on USS?}:::decision F -->|Yes, ovulation confirmed| G[Timed intercourse]:::action F -->|No ovulation| H[Increase to 100 mg, then 150 mg]:::action H --> I{Ovulation achieved?}:::decision I -->|Yes| J[Continue up to 6 cycles]:::action I -->|No after 150 mg| K[Clomiphene-resistant PCOS]:::outcome K --> L[Consider letrozole or gonadotropins]:::action ``` **Mnemonic:** **CLOMIPHENE in PCOS** = **C**yclic **L**uteinizing **O**vulation **M**odulation **I**nduced by **P**ituitary **H**ormone **E**levation for **N**ormal **E**gg release.